P-glycoprotein and its role in drug-drug interactions

Australian Prescriber

Volumn 37, Issue 4, 2014, Pages 137-139

  Finch, Andrew ^a   Pillans, Peter ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Digoxin; Pharmacokinetics

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DABIGATRAN ETEXILATE; DIGOXIN; ERYTHROMYCIN; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; TACROLIMUS; TICAGRELOR; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSPORT; HUMAN; PHARMACODYNAMICS; PROTEIN EXPRESSION;

EID: 84905660550     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2014.050     Document Type: Article

References (10)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localisation of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
2. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:424-9.
3. Konig J, Muller F, Fromm MF. Transporters and drug-drug interactions: Important determinants of drug disposition and effects. Pharmacol Rev 2013;65:944-66.
4. Igel S, Drescher S, Murdter T, Hofmann U, Heinkele G, Tegude H, et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transportermediated efflux. Clin Pharmacokinet 2007;46:777-85.
5. Ho RH, Kim RB. Transporter and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77.
6. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36.
7. Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007;34:1138-44.
8. Sadeque AJM, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68:231-7.
9. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
10. Kawabata M, Yokoyama Y, Sasano T, Hachiya H, Tanaka Y, Yagishita A, et al. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. J Cardiol 2013;62:121-6.